Kyung Im Kim1, Jae Hyun Kim2, Eun Hee Ji3, Jun Ho Jang4, Jin Seok Kim5, Ji-Hyun Kwon6, Inho Kim7,8,9, Seonyang Park7,8,9, Galina Velikova10, Sung-Soo Yoon11,12,13, Jung Mi Oh14,15. 1. College of Pharmacy, Korea University, Sejong, Republic of Korea. 2. College of Pharmacy, Seoul National University, Seoul, Republic of Korea. 3. College of Pharmacy, Gachon University, Incheon, Republic of Korea. 4. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 5. Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. 6. Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea. 7. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. 8. Cancer Research Institute, Seoul National University, Seoul, Republic of Korea. 9. Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. 10. Cancer Research UK Clinical Centre - Leeds, St James's University Hospital, Leeds, UK. 11. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. ssysmc@snu.ac.kr. 12. Cancer Research Institute, Seoul National University, Seoul, Republic of Korea. ssysmc@snu.ac.kr. 13. Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. ssysmc@snu.ac.kr. 14. College of Pharmacy, Seoul National University, Seoul, Republic of Korea. jmoh@snu.ac.kr. 15. Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea. jmoh@snu.ac.kr.
Abstract
PURPOSE: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. METHODS: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. RESULTS: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach's α, except for the scales body image and the inpatient issues. Cronbach's α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. CONCLUSIONS: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.
PURPOSE: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. METHODS: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. RESULTS: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach's α, except for the scales body image and the inpatient issues. Cronbach's α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. CONCLUSIONS: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.
Authors: A M J Braamse; M M J G Gerrits; B van Meijel; O Visser; P van Oppen; A D Boenink; P Cuijpers; P C Huijgens; A T F Beekman; J Dekker Journal: Bone Marrow Transplant Date: 2011-07-04 Impact factor: 5.483
Authors: R P McQuellon; G B Russell; D F Cella; B L Craven; M Brady; A Bonomi; D D Hurd Journal: Bone Marrow Transplant Date: 1997-02 Impact factor: 5.483
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Alois Gratwohl; Helen Baldomero; Michael Gratwohl; Mahmoud Aljurf; Luis Fernando Bouzas; Mary Horowitz; Yoshihisa Kodera; Jeff Lipton; Minako Iida; Marcelo C Pasquini; Jakob Passweg; Jeff Szer; Alejandro Madrigal; Karl Frauendorfer; Dietger Niederwieser Journal: Haematologica Date: 2013-03-18 Impact factor: 9.941
Authors: Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry Storer; Jean E Sanders; Mary E D Flowers; Paul J Martin Journal: JAMA Date: 2004-05-19 Impact factor: 56.272